May 10, 2019
The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.
September 21, 2018
The conference, organized by the Alzheimer's Drug Discovery Foundation, focused on gene therapy and alternative modalities for neurodegenerative diseases, progress in developing novel drugs, as well as the need for new biomarkers.
September 13, 2018
The Alzheimer's Drug Discovery Foundation (ADDF) announces funding for a novel biomarker and two Phase I clinical studies.
April 28, 2017
ADDF grantee Dr. Raymond Scott Turner is recruiting patients for a phase 2 trial of nilotinib—a leukemia drug being tested for treating Alzheimer’s.
April 20, 2017
A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.
February 21, 2017
Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.
September 29, 2016
Dr. Howard Fillit, the ADDF's Founding Executive Director and Chief Science Officer, says: "The ADDF is proud to support a clinical trial that holds such promise for Alzheimer's patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer's."
July 30, 2015
Cleveland Clinic Lou Ruvo Center for Brain Health is recruiting participants for a trial to determine if treatment with rasagiline improves brain glucose metabolism and memory.
January 28, 2015
The ADDF announced today a grant to AgeneBio in support of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment.
June 26, 2014
A peer-reviewed publication from the ADDF and The Michael J. Fox Foundation for Parkinson’s Research offers strategic insight on how organizations can advance the repurposing of FDA-approved drugs for treating neurodegenerative diseases.